Clinical Trial Update: A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST) [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II study of sunitinib malate (SU011248) in patients with gastrointestinal stromal tumors has completed with results posted in 2009.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Sunitinib malate (sunitinib malate)

Snippet

Sponsor: Pfizer | Conditions: Gastrointestinal Stromal Tumors | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2009-11-13